plasma services germany seqirus seqirus global csl behring worldwide americas argentina brazil canada mexico united states asia pacific australia china japan europe austria belgium luxembourg czech republic denmark france germany italy netherlands nordic countries spain switzerland united kingdom csl group global about csl our centenary our businesses our products research and development business development investors corporate responsibility careers newsroom contact csl home home page australian scientists awarded 2.5 m in support of ground breaking research into alzheimer s disease and leukaemia 11 october 2016 two australian scientists have each been awarded an aud 1.25 million five year csl centenary fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand alzheimer s disease . more.fda accepts csl behring s bla for first subcutaneous prophylactic therapy to prevent hereditary angioedema attacks 30 august 2016 csl today announced that the fda has accepted for review csl behring s bla for its low volume subcutaneous sc c1 esterase inhibitor c1 inh human replacement therapy csl830 as prophylaxis to prevent hae attacks . more.other recent news 17 august 2016 dr tadataka tachi yamada kbe has been appointed a director effective from 1 sep 2016 . mr john akehurst has indicated his intention to retire at the conclusion of the company s agm on 12 oct 2016 . more .4 july 2016 csl will be an inaugural partner of the new australian research council industrial transformation training centre for biopharmaceutical innovation to be established at the university of queensland . more .10 june 2016 last night csl behring s australian facility was awarded 2016 victorian manufacturer of the year at the victorian manufacturing hall of fame awards . more . share glossary site map privacy terms of use employees webmaster 2016 csl limited